secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001104659-25-085892
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute gains FDA alignment on streamlined Phase 3 trial design for ersodetug in tumor HI
--------------------------------------------------------------------------------

- FDA agreed to remove double-blind placebo-controlled requirement; study now open-label, single-arm.
- Phase 3 upLIFT trial will enroll as few as 16 patients with tumor hyperinsulinism (HI).
- Topline data from upLIFT expected in the second half of 2026.
- FDA confirmed that the pivotal sunRIZE trial in congenital HI (topline Dec 2025) serves as confirmatory evidence.
- FDA meeting held August 19, 2025; simplified path based on Expanded Access Program outcomes in over 10 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925085892/0001104659-25-085892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925085892/tm2524786d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-085892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer